AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives: Difference between revisions
No edit summary |
m (Bot: Adding CME Category::Cardiology) |
||
(One intermediate revision by one other user not shown) | |||
Line 7: | Line 7: | ||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
|- | |- | ||
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] ( | |colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' OCs may be harmful in women with additional risk factors (eg, cigarette smoking, prior thromboembolic events) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' OCs may be harmful in women with additional risk factors (eg, [[cigarette smoking]], prior thromboembolic events) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' Routine screening for prothrombotic mutations before initiation of hormonal contraception is not useful. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' Routine screening for prothrombotic mutations before initiation of [[hormonal contraception]] is not useful. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Line 25: | Line 25: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIb]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIb]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki> Among OC users, aggressive therapy of stroke risk factors may be reasonable. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki> Among OC users, aggressive therapy of [[stroke]] risk factors may be reasonable. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Aging-associated diseases]] | [[Category:Aging-associated diseases]] | ||
Line 42: | Line 46: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 19:37, 14 March 2016
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
FDA on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
CDC on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives in the news | |
Blogs on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)[1]
Class III (Harm) |
"1. OCs may be harmful in women with additional risk factors (eg, cigarette smoking, prior thromboembolic events) (Level of Evidence: B) " |
"2. Routine screening for prothrombotic mutations before initiation of hormonal contraception is not useful. (Level of Evidence: A) " |
Class I |
" Measurement of BP before initiation of hormonal contraception is recommended. (Level of Evidence: B) " |
Class IIb |
" Among OC users, aggressive therapy of stroke risk factors may be reasonable. (Level of Evidence: C)" |
References
- ↑ Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL; et al. (2014). "Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. doi:10.1161/01.str.0000442009.06663.48. PMID 24503673.